BACKGROUND: Cardiac retransplantation remains the most viable option for patients with allograft heart failure; however, careful patient selection is paramount considering limited allograft resources. We analyzed clinical outcomes following retransplantation in an academic, tertiary care institution. METHODS: Between 1981 and 2011, 593 heart transplantations, including 22 retransplantations were performed at our institution. We analyzed the preoperative demographic characteristics, cause of allograft loss, short- and long-term surgical outcomes and cause of death among patients who had cardiac retransplantations. RESULTS: Twenty-two patients underwent retransplantation: 10 for graft vascular disease, 7 for acute rejection and 5 for primary graft failure. Mean age at retransplantation was 43 (standard deviation [SD] 15) years; 6 patients were women. Thirteen patients were critically ill preoperatively, requiring inotropes and/or mechanical support. The median interval between primary and retransplantation was 2.2 (range 0-16) years. Thirty-day mortality was 31.8%, and conditional (> 30 d) 1-, 5- and 10-year survival after retransplantation were 93%, 79% and 59%, respectively. A diagnosis of allograft vasculopathy (p = 0.008) and an interval between primary and retransplantation greater than 1 year (p = 0.016) had a significantly favourable impact on 30-day mortality. The median and mean survival after retransplantation were 3.3 and 5 (SD 6, range 0-18) years, respectively; graft vascular disease and multiorgan failure were the most common causes of death. CONCLUSION: Long-term outcomes for primary and retransplantation are similar if patients survive the 30-day postoperative period. Retransplantation within 1 year of the primary transplantation resulted in a high perioperative mortality and thus may be a contraindication to retransplantation.
BACKGROUND: Cardiac retransplantation remains the most viable option for patients with allograft heart failure; however, careful patient selection is paramount considering limited allograft resources. We analyzed clinical outcomes following retransplantation in an academic, tertiary care institution. METHODS: Between 1981 and 2011, 593 heart transplantations, including 22 retransplantations were performed at our institution. We analyzed the preoperative demographic characteristics, cause of allograft loss, short- and long-term surgical outcomes and cause of death among patients who had cardiac retransplantations. RESULTS: Twenty-two patients underwent retransplantation: 10 for graft vascular disease, 7 for acute rejection and 5 for primary graft failure. Mean age at retransplantation was 43 (standard deviation [SD] 15) years; 6 patients were women. Thirteen patients were critically ill preoperatively, requiring inotropes and/or mechanical support. The median interval between primary and retransplantation was 2.2 (range 0-16) years. Thirty-day mortality was 31.8%, and conditional (> 30 d) 1-, 5- and 10-year survival after retransplantation were 93%, 79% and 59%, respectively. A diagnosis of allograft vasculopathy (p = 0.008) and an interval between primary and retransplantation greater than 1 year (p = 0.016) had a significantly favourable impact on 30-day mortality. The median and mean survival after retransplantation were 3.3 and 5 (SD 6, range 0-18) years, respectively; graft vascular disease and multiorgan failure were the most common causes of death. CONCLUSION: Long-term outcomes for primary and retransplantation are similar if patients survive the 30-day postoperative period. Retransplantation within 1 year of the primary transplantation resulted in a high perioperative mortality and thus may be a contraindication to retransplantation.
Authors: J C Magee; M L Barr; G P Basadonna; M R Johnson; S Mahadevan; M A McBride; D E Schaubel; A B Leichtman Journal: Am J Transplant Date: 2007 Impact factor: 8.086
Authors: Veli K Topkara; Nicholas C Dang; Ranjit John; Faisal H Cheema; Raffaele Barbato; Marco Cavallo; Judy F Liu; Lorraine M Liang; Elyse A Liberman; Michael Argenziano; Mehmet C Oz; Yoshifumi Naka Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Heidi Goerler; Andre Simon; Bernhard Gohrbandt; Christian Hagl; Petra Oppelt; Axel Haverich; Martin Strueber Journal: Eur J Cardiothorac Surg Date: 2008-08-09 Impact factor: 4.191
Authors: Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller Journal: Circulation Date: 2007-07-16 Impact factor: 29.690
Authors: Pavan Atluri; William Hiesinger; Robert C Gorman; Alberto Pochettino; Mariell Jessup; Michael A Acker; Rohinton J Morris; Y Joseph Woo Journal: J Cardiothorac Surg Date: 2008-05-07 Impact factor: 1.637
Authors: Nicola Vistarini; Anthony Nguyen; Michel White; Normand Racine; Louis P Perrault; Anique Ducharme; Denis Bouchard; Philippe Demers; Michel Pellerin; Yoan Lamarche; Ismaïl El-Hamamsy; Geneviève Giraldeau; Guy Pelletier; Michel Carrier Journal: Can J Surg Date: 2017-09 Impact factor: 2.089